touchTALKS Understanding the pathophysiology of multiple sclerosis and the development of new therapies
Prof. Tobias Derfuss reviews the cellular model of disease in multiple sclerosis, and how pathophysiology can offer novel therapeutic targets.
The role of immune cells in MS pathogenesis
Prof. Tobias Derfuss outlines the cellular model of multiple sclerosis, including the role of immune cells in disease pathogenesis.view bio and disclosures 1/3 Next Chapter
Pathogenic mechanisms as therapeutic targets
Prof. Tobias Derfuss reviews the available disease-modifying therapies for multiple sclerosis and how their mechanisms of action target the pathobiology of the disease.view bio and disclosures 2/3 Next Chapter
A new therapeutic target: Bruton’s tyrosine kinase
Prof. Tobias Derfuss discusses the mechanism of action and the latest clinical trial data for Bruton’s tyrosine kinase inhibitors.view bio and disclosures 3/3 Take CE/CME Test
Learning Objectives & Overview
In this activity, Prof. Tobias Derfuss outlines the role of immune cells in driving multiple sclerosis pathogenesis, explains how the pathobiology of the disease has driven the development of disease-modifying therapies, and reviews the mechanism of action and clinical trial landscape for Bruton’s tyrosine kinase inhibitors.
This activity is jointly provided by USF Health and touchIME. read more
This activity has been designed to meet the educational needs of general neurologists, MS specialists and MS nurses involved in the management of multiple sclerosis.
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Prof. Tobias Derfuss discloses: Consultancy fees from Alexion, Biogen, Celgene, GeNeuro, MedDay, Merck, Novartis, and Sanofi. Grant/research support from Merck, Novartis, and Roche.
Niraja S. Suresh, MD discloses: Advisory board or panel fees from Alexion, Alnylam Pharmaceuticals, Argenx, (relationships terminated) and Collegium Pharmaceutical. Speakers’ Bureau fees from Takeda.
Touch Medical Director
Holly Gilbert-Jones and Kathy Day have no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact firstname.lastname@example.org
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 13 March 2023. Date credits expire: 13 March 2024.
If you have any questions regarding credit please contact email@example.com
After watching this activity, participants should be better able to:
- Explain the cellular model of disease in multiple sclerosis
- Explain how the pathobiology of multiple sclerosis drives the development of disease-modifying therapies
- Summarize the mechanism of action of Bruton’s tyrosine kinase inhibitors and how this may translate into clinical benefits for patients with multiple sclerosis
Faculty & Disclosures
Prof. Tobias Derfuss
University Hospital Basel, Switzerland
Prof. Tobias Derfuss is the head of the outpatient care unit and deputy head of the MS Center at the Department of Neurology, University Hospital Basel, Switzerland, and research group leader in clinical neuroimmunology at the Department of Biomedicine at the University of Basel. read more
He is a clinical neurologist, specializing in neuroimmunology. Prof. Derfuss undertook his clinical training at the Department of Neurology, Klinikum Grosshadern in Munich, Germany. His research at the Max-Planck Institute for Neurobiology, Department of Neuroimmunology, was focused on the discovery of new autoantigens in multiple sclerosis (MS) and the characterization of the immune response against latent herpes viruses. After training in neuromuscular diseases at the Friedrich-Baur Institute and in psychiatry at the Max-Planck Institute for Psychiatry in Munich, he was appointed head of the outpatient department and MS clinic in the Department of Neurology at the University Hospital Erlangen in 2009.
Since 2010, he has been professor and senior physician at the Department of Neurology and research group leader at the Department of Biomedicine at the University Hospital Basel. His main research focus is the discovery of biomarkers and analysing the mode of action of disease-modifying treatments in neuroinflammatory diseases. Prof. Derfuss is also involved in the design and conduct of clinical trials for newly emerging therapies in MS.
Prof. Tobias Derfuss discloses: Consultancy fees from Alexion, Biogen, Celgene, GeNeuro, MedDay, Merck, Novartis and Sanofi. Grants/research support from Merck, Novartis and Roche.
REGISTER NOW FOR FREE ACCESS TO
- 1000+ topical and insightful peer-reviewed journal articles
- 100+ hours of bite-sized congress highlights
- 8 major therapy areas packed with the latest scientific advances
- 150+ specialties offering learn-on-the-go medical education
- + Concise email updates and newsletters so you never miss out